



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/656,873	09/05/2003	Mark C. Fishman	00786/381003	8749

21559 7590 06/19/2006

CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110

EXAMINER

SITTON, JEHANNE SOUAYA

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 06/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/656,873

Applicant(s)

FISHMAN ET AL.

Examiner

Jehanne S. Sitton

Art Unit

1634

– The MAILING DATE of this communication appears on the cover sheet with the correspondence address –

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 May 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) 8-19 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7 and 20 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>9/2003, 1/2005</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Applicant's election without traverse of Group 1 in the reply filed on 5/9/2006 is acknowledged. An action on the merits of group 1, directed to claims 1-7 and 20 follows.

Priority

2. Applicants claim for priority to provisional application 60/175,787, filed 1/12/2000 is acknowledged. It is noted, however, that the '787 application does not disclose the genotype of the pickwick mutation.

Specification

3. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1-7 and 20 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with

Art Unit: 1634

which it is most nearly connected, to make and/or use the invention. There are many factors to be considered when determining whether there is sufficient evidence to support determination that a disclosure does not satisfy the enablement requirements and whether any necessary experimentation is undue. These factors have been described by the court in *In re Wands*, 8 USPQ2d 1400 (CA FC 1988). *Wands* states at page 1404,

“Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in *Ex parte Forman*. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.”

The nature of the invention and the breadth of the claims:

The claims are broadly drawn to a method for determining whether a test subject from any source, including mammals and humans, has, is at risk of developing, may have or may be at risk of developing *any* titin related disease or condition of the heart by detecting *any* mutation from a titin gene. The claims are further limited to heart failure, and the “pickwick” mutation.

The nature of the invention, therefore, requires the knowledge of predictive associations between any mutation in a titin gene from any subject and an association with any condition or disease of the heart. The invention further requires the ability to identify the “pickwick” mutation in any subject from any species.

The amount of direction or guidance and presence and absence of working examples:

The specification teaches that heart disease is a general term used to describe different heart conditions. The specification teaches that risk factors include coronary artery disease,

Art Unit: 1634

hypertension, valvular heart disease, cardiomyopathy, disease of the heart muscle, obesity, diabetes, and family history of heart failure (see page 1). The specification teaches that during a mutation screening of zebra fish, a phenotype resulting from mutation of the titin gene was observed which was similar to mammalian heart failure (page 1).

The specification teaches that the claimed recitation of a “titin gene” is drawn to a nucleic acid that encodes a titin protein or polypeptide that has 45%, 60%, 75% and 90% identity to the sequence of human or zebra fish titin molecules (see p. 3). Such a recitation encompasses mutants, allelic variants, and homologs of titin from any source, which have not been taught or described in the specification. The specification further defines “titin related disease or condition” to mean a disease or condition that results from an inappropriately high or low expression of a titin gene or a mutation in a titin gene that alters the biological activity of a titin nucleic acid or polypeptide. Therefore, the recitation encompasses any substitution, deletion or insertion in any titin gene. The specification teaches that the methods include diagnostic assessment of heart disease, heart failure (page 8, first full para), congestive heart failure, and coronary artery diseases or conditions associated with valve formation defects (page 9). The specification, however, has only taught a single mutation in the N2B exon of titin that was found in zebra fish embryos characterized with a weak heartbeat (see p. 20). Further, the whereabouts of this mutation in the N2B exon are unclear as the specification only teaches that identification of a T-G transition in the *pikm171* allele was found which resulted in a change of leucine in the IS3 fragment of N2B domain into a stop codon. The specification, however, does not teach at which leucine residue this mutation occurs. In addition, the specification does not define the specific genotype of the *pickwick* mutation. The specification recites “a mutation in a cardiac

Art Unit: 1634

specific exon, such as the N2B exon, e.g. the *pickwick* mutation” (see p. 2, lines 9-10), thus it is unclear from this recitation or the teachings in the specification as to what is encompassed by the *pickwick* mutation. Xu (Xu et al; Nature Genetics, vol. 30, pages 205-209; 2002) teaches that there are multiple alleles in the *pik* complementation group (see abstract), however the specification provides no description of the other alleles. This recitation, therefore, appears to encompass any mutation with the *pickwick* phenotype (p. 19, lines 4-5). However, the specification has only taught a single mutation that appears to be associated with a weak heart beat in zebra fish embryos, but the specific genotype of this mutation is not taught.

The specification has not taught any working examples of any other mutations in the titin gene from zebra fish, or any other species including any mammals or human population, which is associated with a titin related disease or condition of the heart. Further, the specification has not taught an association between the pickwick mutation and any of the diseases or conditions which is encompassed by the claims, in zebra fish or in any other species, including mammals. Although the specification teaches that the pickwick mutation is associated with a weak heartbeat in zebra fish, which may be similar to mammalian heart failure, such is not necessarily diagnostic of mammalian heart failure, let alone any disease or condition of the heart in any mammal or human. While a weak heart beat may lead to heart failure, there are other causes for heart failure including coronary artery disease, hypertension and diabetes (as taught by the specification at page 1). Therefore, while coronary artery disease, hypertension, or diabetes may all lead to heart failure, a mutation which is associated with any one of these disease or conditions is not necessarily *diagnostic* of another. Each represents a specific disease which have different symptoms and causes. The specification has not established a universal

Art Unit: 1634

correlation between any mutation in any titin gene and an association with any disease or condition of the heart as is broadly claimed.

The specification does not teach or provide any guidance as to which regions or amino acids in the titin gene would be affected to provide for the diagnostic associations set forth in the claims. The specification teaches a single phenotype, the pickwick mutation, but does not teach what this position is in the titin gene from zebra fish or any other species, nor does it teach if the T to G tranversion even exists in other species. The specification does not teach what other positions within the titin gene of zebra fish or the titin gene from other species would provide the same phenotype or whether a polymorphism would have the same effect in another gene. The specification provides no guidance as to conserved and nonconserved positions in titin from different species.

The state of the prior art and the predictability or unpredictability of the art:

While the claims are broadly drawn to detecting any mutation in any region of the titin gene and association to any disease or condition of the heart, Garvey (Garvey et al; Genomics, vol. 79, pages 146-149, 2002) teaches that titin is differentially spliced with a cardiac muscle isoform N2B and a skeletal muscle isoform N2A (see page 146, col. 2). Garvey teaches a mutation in mouse titin which disrupts the N2A domain but which was not associated with any cardiac muscle pathology. Accordingly, it is clear that a mutation or polymorphism in “any region” of titin is not universally correlative of an association with heart disease. This lack of universal association is also true of the cardiac isoform of human titin. For example, Itoh-Satoh et al (Biochemical and Biophysical Research Communications, vol. 291, pp 385-393; 2002)

Art Unit: 1634

teach a mutation in the titin gene which may be associated with Dilated Cardiomyopathy (p. 387, col. 2, lines 7-13), but another mutation, Arg328Cys, was found in healthy control subjects, indicating that it is a polymorphism not related with DCM (col. 2, lines 3-5). Additionally, Siu (Siu et al; Circulation, March 1999, vol. 99, pages 1022-1026) teaches that five variations were found in the N2B region of human titin, including 3 which did not alter the protein sequence and 2 which did, but that were determined to not be disease-causing mutations (page 1025, col. 2).

The prior art provides no analysis of mutations in titin and comparisons to similar positions across species. The prior art does not provide any analysis of titin function with regard to mutational analysis nor does it provide any indication of mutations in regions of titin which would be associated with heart disease or conditions. The post filing date art of Itoh-Satoh teaches a number of mutations in human titin, but also provides alignments across different species. As seen in figures 1 and 2, the amino acid positions are not necessarily conserved across different species, especially noting the differences found in the Z line region between chicken and human titin sequences.

The level of skill in the art:

The level of skill in the art is deemed to be high.

The quantity of experimentation necessary:

The teachings of the specification are insufficient to provide one of skill in the art with a predictable correlation that any substitution, deletion or insertion in the titin gene, or more specifically the IS3 fragment of N2B would result in a weak heartbeat in zebra fish embryos or

Art Unit: 1634

any other species. The single point mutation, whose location is not taught, set forth in the specification also does not provide one of skill in the art with a predictable correlation between any mutations in any titin gene from any source and any disease or condition of the heart, including heart failure. The specification lacks sufficient guidance to enable one of skill in the art to make or use the invention as broadly as it is claimed, without undue experimentation.

To practice the invention as broadly as it is claimed the skilled artisan would have perform an enormous amount of research to mutate each position of the titin gene from each species, which encodes a protein which is on the order of 27,000 amino acids, and perform functional analysis to determine which positions and what alterations are associated with diseases or conditions of the heart. The skilled artisan would then be required to perform a large study which included subjects affected with a large number of different diseases or conditions of the heart as well as controls and to screen such for any mutation in a titin gene to determine which mutations were predictably correlative of disease and which were not. Such analysis would consist of unpredictable trial and error research projects as evidenced by the art cited above. An enormous amount of inventive effort would be required for these research projects, with each intervening step not being predictive of any particular outcome. For example, given the lack of guidance in the specification and the art, the skilled artisan would not have been able to predict the mutations taught by Itoh-Satoh nor would the skilled artisan have been able to distinguish which of the mutations taught by Siu and Itoh-Satoh are associated with disease as opposed to those that are not.

It is known for nucleic acids as well as proteins that a single nucleotide or amino acid change or mutation can alter the function of the biomolecule in some instances. Given the lack

Art Unit: 1634

of guidance in the art at the time the invention was made as well as the lack of guidance in the specification, the effects of these changes are unpredictable as to which ones have a significant effect versus not. The specification has not provided the skilled artisan with any teaching or guidance as to which nucleotide or amino acid positions in the titin gene would be responsible for normal or aberrant activity of the titin protein. Without such, the skilled artisan would further be unable to predictably correlate which mutations would have and would not have an effect on the function or activity of any titin protein. The art exemplifies this unpredictability.

Thus given the broad claims in an art whose nature is identified as unpredictable, the unpredictability of that art, the large quantity of research required to define these unpredictable variables, the lack of guidance provided in the specification, the absence of a working example and the negative teachings in the prior art balanced only against the high skill level in the art, it is the position of the examiner that it would require undue experimentation for one of skill in the art to perform the method of the claim as broadly written.

Written Description

6. Claims 1-7 and 20 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are broadly drawn to a method for determining whether a test subject from any source, including mammals and humans, has, is at risk of developing, may have or may be at

Art Unit: 1634

risk of developing *any* titin related disease or condition of the heart by detecting *any* mutation from a titin gene. The claims are further limited to heart failure, and the “pickwick” mutation.

The specification teaches that during a mutation screening of zebra fish, a phenotype resulting from mutation of the titin gene was observed which was similar to mammalian heart failure (page 1). The specification teaches that the claimed recitation of a “titin gene” is drawn to a nucleic acid that encodes a titin protein or polypeptide that has 45%, 60%, 75% and 90% identity to the sequence of human or zebra fish titin molecules (see p. 3). Such a recitation encompasses mutants, allelic variants, and homologs of titin from any source, which have not been taught or described in the specification. The specification further defines “titin related disease or condition” to mean a disease or condition that results from an inappropriately high or low expression of a titin gene or a mutation in a titin gene that alters the biological activity of a titin nucleic acid or polypeptide. Therefore, the recitation encompasses any substitution, deletion or insertion in any titin gene. The specification asserts that the methods include diagnostic assessment of heart disease, heart failure (page 8, first full para), congestive heart failure, and coronary artery diseases or conditions associated with valve formation defects (page 9). The specification, however, has only taught a single mutation in the N2B exon of titin that was found in zebra fish embryos characterized with a weak heartbeat (see p. 20). Further, the whereabouts of this mutation in the N2B exon are unclear as the specification only teaches that identification of a T-G transition in the *pikm171* allele was found which resulted in a change of leucine in the IS3 fragment of N2B domain into a stop codon. The specification, however, does not teach at which leucine residue this mutation occurs. In addition, the specification does not define the specific genotype of the *pickwick* mutation. The specification recites “a mutation in a

Art Unit: 1634

cardiac specific exon, such as the N2B exon, e.g. the *pickwick* mutation” (see p. 2, lines 9-10), thus it is unclear from this recitation or the teachings in the specification as to what is encompassed by the *pickwick* mutation. Xu (Xu et al; Nature Genetics, vol. 30, pages 205-209; 2002) teaches that there are multiple alleles in the *pik* complementation group (see abstract), however the specification provides no description of the other alleles. This recitation, therefore, appears to encompass any mutation with the *pickwick* phenotype (p. 19, lines 4-5). The specification, however, has only taught a single mutation that appears to be associated with a weak heart beat in zebra fish embryos, but the specific genotype of this mutation is not taught.

The specification provides insufficient written description to support the genus of titin genes or mutations encompassed by the claims. The claims encompass a large genus of nucleic acids which comprise mutations in any region of a titin gene from any species. The genus includes an enormous number of polymorphisms and mutations for which no written description is provided in the specification. For example, the art of Itoh-Satoh provides for mutation which have not been taught or described in the specification in any way. The large genus encompassed by the claimed is represented in the specification by only the generally described single mutation which is associated with the “pickwick” phenotype. The specification does not teach the specific location of this mutation in the titin gene from zebra fish nor does it teach what a corresponding position would be in any other species. Thus, applicant has express possession of only a single undefined mutation in a genus which comprises hundreds of millions of different possibilities. Here, no common element or attributes of the sequences are disclosed which would permit selection of sequences as polymorphisms or mutations. No structural limitations or requirements which provide guidance on the identification of sequences which meet these functional

Art Unit: 1634

limitations of associating a polymorphism with diagnosis of or indicative of increased risk of developing any disease or condition of the heart.
or may have or be at risk of developing

Further, these claims expressly encompass allelic variants including insertions, deletion, substitutions and transversions at thousands of different sites. However, no predictable correlation between the structural alterations of the single polymorphism and heart disease is provided by the specification. Therefore, the skilled artisan would be unable to predictably correlate any other structural change in any other region of titin from “any” species and an association with any disease or condition of the heart as is broadly claimed. Additionally, claim 7 is drawn to “the pickwick” mutation, but the specification provides no clear definition of what mutations are encompassed by the term “pickwick” or the specific location of the single polymorphism taught in the specification.

The specification provides no correlation between the structure of mutations in titin and the function of such mutations with diseases or conditions of the heart. The mutation shown is not representative of the enormous genus of structurally and functionally distinct mutations which would be associated with the large number of different diseases and conditions of the heart because it is not known which mutations would have the same affect.

In analysis of the claims for compliance with the written description requirement of 35 U.S.C. 112, first paragraph, the written description guidelines note regarding genus/species situations that “Satisfactory disclosure of a `representative number` depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features of the elements possessed by the members of the genus in view of the species disclosed.” (See: Federal Register: December 21, 1999 (Volume 64, Number 244),

Art Unit: 1634

revised guidelines for written description.) In the instant case, the specification fails to teach the necessary common attributes or features of the genus of encompassed nucleic acids and mutations in view of the single species disclosed. As such, one of skill in the art would not recognize that applicant was in possession of the genus of nucleic acids and polymorphisms encompassed by the broadly claimed invention.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

The skilled artisan cannot envision the detailed chemical structure of the encompassed nucleic acids and mutations, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The nucleic acid itself is required. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993), and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. The current situation is a definition of the compound solely based on its functional utility, as a polymorphism, without any definition of the particular polymorphisms claimed.

Finally, University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404, 1405 held that:

To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." Lockwood v. American Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); In re Gosteli, 872 F.2d

Art Unit: 1634

1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." Lockwood, 107 F.3d at 1572, 41 USPQ2d at 1966.

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. Fiers v. Revel, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself." Id. at 1170, 25 USPQ2d at 1606.

7. Claims 1-7 and 20 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a NEW MATTER rejection.

The claims have been amended to recite, "may have or be at risk of developing", however the specification does not appear to provide support for this amendment. It appears the amendment has been made to alter the scope encompassed by the claims, however it is unclear how "may have or be at risk of developing" is different in scope than "risk of developing". In other words, what is the change in scope encompassed by determining that someone or some subject is "at risk of developing" vs determining that they "may have" or "may be at risk of developing" a disease or condition? The specification asserts, at page 7, that the diagnostic methods make it possible to detect "an increased likelihood of heart disease". At page 8, the specification recites "diagnostic methods can be used with patients that have not yet developed heart failure but who are at risk of developing such a disease, or with patients that are at an early stage of developing such a disease". At page 9, the specification asserts that the methods can be

Art Unit: 1634

used to identify parents who may be carriers of a recessive titin mutation. However, none of these recitations provide for diagnostic methods of subjects who “may have or [may] be at risk of developing a titin related disease or condition...”. The specification provides no support for this new recitation nor does it provide any guidance as to how to assess this apparent attempt at alteration in claimed scope. Accordingly, the amendment appears to have introduced new matter into the claimed invention.

Claim Rejections - 35 USC § 102

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

9. Claims 1-6 and 20 are rejected under 35 U.S.C. 102(a) as being anticipated by Satoh et al (Biochemical and Biophysical Research Communications, vol. 262, pp 411-417, 1999).

With regard to claims 1, 4-6, and 20, Satoh teaches of an A to T transversion in codon 740 of the titin gene of a patient with hypertrophic cardiomyopathy, which replaces an Arginine with Leucine (see abstract). Satoh teaches that this mutation was not found in more than 500 normal chromosomes (see abstract). With regard to claims 2 and 3, Satoh teaches that genomic DNA was extracted from each subject and that PCR primers flanking each exon of the titin gene were designed to amplify each exon (p. 412-col. 1, “PCR-DCP analysis”) and that to identify the

Art Unit: 1634

mutation in exon 14, the PCR product was cloned into a vector and sequenced (para. bridging cols 1 and 2, p. 412).

Conclusion

10. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Jackel et al; FEBS, vol. 408, pages 21-24; 1997, teaches a deletion in the titin gene in a Hamster kidney cell line. Jackel teaches that this mutation occurred in subculture and was not present in the DNA of the species of origin or the cell line which the BHK-21 Bi originated from. Accordingly, Jackel does not teach determining "a titin related disease or condition of the heart".

11. No claims are allowed.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Sitton whose telephone number is (571) 272-0752. The examiner can normally be reached Monday-Thursday from 8:00 AM to 5:00 PM and on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571) 272-0735. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Art Unit: 1634

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.



Jehanne Sitton
Primary Examiner
Art Unit 1634

6/13/06